Ingrid Delaet Sells 4,367 Shares of Neurocrine Biosciences (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Ingrid Delaet sold 4,367 shares of the business’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $181.02, for a total transaction of $790,514.34. Following the sale, the insider directly owned 16,225 shares in the company, valued at approximately $2,937,049.50. This represents a 21.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ingrid Delaet also recently made the following trade(s):

• On Tuesday, July 7th, Ingrid Delaet sold 3,401 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $178.57, for a total transaction of $607,316.57.
• On Wednesday, July 8th, Ingrid Delaet sold 2,737 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $178.54, for a total value of $488,663.98.
• On Thursday, July 9th, Ingrid Delaet sold 8,433 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $178.72, for a total value of $1,507,145.76.
• On Friday, May 29th, Ingrid Delaet sold 2,261 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $156.71, for a total transaction of $354,321.31.

Neurocrine Biosciences Trading Down 1.8%

Shares of NBIX stock traded down $3.12 during trading hours on Monday, hitting $173.99. The company’s stock had a trading volume of 1,573,039 shares, compared to its average volume of 1,184,527. The business has a fifty day moving average of $160.84 and a 200-day moving average of $142.87. The stock has a market cap of $17.49 billion, a price-to-earnings ratio of 26.81, a P/E/G ratio of 0.71 and a beta of 0.39. Neurocrine Biosciences, Inc. has a twelve month low of $122.14 and a twelve month high of $181.18.

Hedge Funds Weigh In On Neurocrine Biosciences

Several institutional investors have recently added to or reduced their stakes in the business. NewEdge Advisors LLC lifted its position in Neurocrine Biosciences by 0.5% during the first quarter. NewEdge Advisors LLC now owns 13,066 shares of the company’s stock worth $1,721,000 after buying an additional 68 shares during the period. Huntington National Bank increased its stake in shares of Neurocrine Biosciences by 12.6% during the 4th quarter. Huntington National Bank now owns 678 shares of the company’s stock valued at $96,000 after acquiring an additional 76 shares during the last quarter. Perigon Wealth Management LLC lifted its holdings in shares of Neurocrine Biosciences by 3.1% during the 4th quarter. Perigon Wealth Management LLC now owns 2,590 shares of the company’s stock worth $367,000 after acquiring an additional 78 shares during the period. Motley Fool Asset Management LLC lifted its holdings in shares of Neurocrine Biosciences by 4.8% during the 4th quarter. Motley Fool Asset Management LLC now owns 1,693 shares of the company’s stock worth $240,000 after acquiring an additional 78 shares during the period. Finally, Main Management ETF Advisors LLC boosted its position in shares of Neurocrine Biosciences by 1.0% in the fourth quarter. Main Management ETF Advisors LLC now owns 7,830 shares of the company’s stock worth $1,111,000 after acquiring an additional 80 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently commented on NBIX. Piper Sandler increased their price objective on Neurocrine Biosciences from $190.00 to $207.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. BMO Capital Markets upped their target price on shares of Neurocrine Biosciences from $144.00 to $170.00 and gave the company a “market perform” rating in a report on Monday. Truist Financial upped their target price on shares of Neurocrine Biosciences from $155.00 to $200.00 and gave the company a “buy” rating in a report on Monday. The Goldman Sachs Group started coverage on shares of Neurocrine Biosciences in a report on Tuesday, June 2nd. They set a “buy” rating and a $213.00 price target for the company. Finally, Wall Street Zen raised shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 25th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $191.67.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research?driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.